1. Academic Validation
  2. Opposite physiological and pathological mTORC1-mediated roles of the CB1 receptor in regulating renal tubular function

Opposite physiological and pathological mTORC1-mediated roles of the CB1 receptor in regulating renal tubular function

  • Nat Commun. 2022 Apr 4;13(1):1783. doi: 10.1038/s41467-022-29124-8.
Liad Hinden 1 Majdoleen Ahmad 1 Sharleen Hamad 1 Alina Nemirovski 1 Gergő Szanda 2 Sandra Glasmacher 3 Aviram Kogot-Levin 4 Rinat Abramovitch 5 6 Bernard Thorens 7 Jürg Gertsch 3 Gil Leibowitz 4 Joseph Tam 8
Affiliations

Affiliations

  • 1 Obesity and Metabolism Laboratory, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • 2 Department of Physiology, Semmelweis University, Budapest, Hungary.
  • 3 Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland.
  • 4 Diabetes Unit and Endocrine Service, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • 5 The Wohl Institute for Translational Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • 6 The Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • 7 Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland.
  • 8 Obesity and Metabolism Laboratory, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. [email protected].
Abstract

Activation of the cannabinoid-1 receptor (CB1R) and the mammalian target of rapamycin complex 1 (mTORC1) in the renal proximal tubular cells (RPTCs) contributes to the development of diabetic kidney disease (DKD). However, the CB1R/mTORC1 signaling axis in the kidney has not been described yet. We show here that hyperglycemia-induced endocannabinoid/CB1R stimulation increased mTORC1 activity, enhancing the transcription of the facilitative glucose transporter 2 (GLUT2) and leading to the development of DKD in mice; this effect was ameliorated by specific RPTCs ablation of GLUT2. Conversely, CB1R maintained the normal activity of mTORC1 by preventing the cellular excess of Amino acids during normoglycemia. Our findings highlight a novel molecular mechanism by which the activation of mTORC1 in RPTCs is tightly controlled by CB1R, either by enhancing the reabsorption of glucose and inducing kidney dysfunction in diabetes or by preventing amino acid uptake and maintaining normal kidney function in healthy conditions.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-18697
    98.05%, CB1 Receptor Antagonist
  • HY-117771
    98.28%, DAGLα Inhibitor